What is Galmed Pharmaceuticals Ltd. (GLMD)?

Galmed Pharmaceuticals Ltd. (GLMD) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of GLMD?

The current price of GLMD is $4.63. Prices are updated in real time on Stocks360.

What is GLMD's price-to-earnings (PE) ratio?

GLMD's trailing twelve-month PE ratio is -0.34, based on current price and earnings per share data available on Stocks360.

What is GLMD's market capitalization?

GLMD's market capitalization is $4,782,183.00, placing it in the small-cap tier.

Galmed Pharmaceuticals Ltd. (GLMD)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$4.63

Market Cap

$4.78M

PE (TTM)

-0.34

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.67

Day Range

$3.82 – $4.63

52-wk Range

$3.29 – $13.20

Avg Volume

N/A

Volume

301.15K

Galmed Pharmaceuticals Ltd. (GLMD) is a publicly traded company in the Healthcare sector. Latest price: $4.63. Market cap $4.78M. Trailing PE -0.34. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-27 · $11.04 2026-10-05 · $3.45 (-68.75%)

Earnings

Most Recent

Sep 2, 2026

EPS $-2.86 vs est. $-3.12

Beat by $0.26

Next Earnings

Nov 25, 2026

EPS estimate $-3.12

Proprietary Signals

Signal snapshot temporarily unavailable.

About Galmed Pharmaceuticals Ltd.

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.34×
P/S (TTM)	0.00×
P/B	0.35×
P/FCF (TTM)	-0.56×
EV / EBITDA	-0.16×
EV / Sales	0.00×
Earnings Yield	-257.30%
Free Cash Flow Yield	-178.64%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.87M
Net Income (TTM)	-$12.30M
Free Cash Flow (TTM)	-$8.44M
Net Debt	-$2.92M
Working Capital	$8.90M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-73.68%
Return on Invested Capital	-64.02%